Dean Rudge
Senior Reporter
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Samsung Bioepis Also Faces 2029 Wait For US Etanercept Biosimilar
Samsung Bioepis’ etanercept biosimilar, freely available in Europe, will not be sold in the US until patent expiry in 2029 following action by a US district court.
Bankrupt Teligent Announces Opening Bids Totaling $64m For Its Assets
Opening bids totaling $64m have been submitted for bankrupt Teligent’s assets across the US and Canada, weeks after the injectables specialist entered Chapter 11 bankruptcy proceedings.
Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan
A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.
Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss
Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.
US Industry Welcomes Nomination Of Califf To FDA Helm For A Second Time
The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.
Rovi Remains ‘Bullish’ On Enoxaparin Biosimilar With Much Room To Grow
Spain’s Laboratorios Farmaceuticos Rovi has set out why it remains confident in its prospects for its Becat (enoxaparin) biosimilar to Sanofi’s Lovenox/Clexane while providing an update for the firm’s Doria once-a-month injectable formulation of risperidone.